Oncology
2 drugs are in development for Follicular Lymphoma.
- Companies
- 2
- Clinical trials
- 46
BioSniper AIPage evidence connected
Prepared research question
Which programs lead the Follicular Lymphoma pipeline—and what evidence could change the picture?
Run cited research
Traceable citations · Unknowns marked
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| tazverik | Epizyme, Inc. (EPZM) |
Phase 1(1)
| Drug | Company |
|---|---|
| CTX112 | CRISPR Therapeutics AG (CRSP) |
About this indication
Follicular Lymphoma context
Oncology·MeSH: Lymphoma, Follicular (D008224)
Also known as: Brill Symmers Disease, Follicular Lymphoma, Giant, Follicular Lymphomas, Follicular Lymphomas, Giant, Lymphomas, Nodular, Nodular Lymphoma
Prevalence
56.0 / 100K
Incidence
19.6 / 100K/yr
Frequently asked questions
How many drugs are in development for Follicular Lymphoma?
BioSniper tracks 2 drugs in development for Follicular Lymphoma across 2 companies.
How many clinical trials target Follicular Lymphoma?
There are 46 clinical trials targeting Follicular Lymphoma tracked by BioSniper.
What is the prevalence of Follicular Lymphoma?
The estimated prevalence of Follicular Lymphoma is approximately 56.0 per 100,000 population.